{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:09:44Z","timestamp":1762445384005,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.061","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:11:17Z","timestamp":1675066277000},"page":"1537-1540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011\u2013August 2019"],"prefix":"10.1016","volume":"41","author":[{"given":"Srihari","family":"Seshadri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Limone C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"766\u201374","key":"10.1016\/j.vaccine.2023.01.061_b0005","first-page":"74A","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.01.061_b0010","doi-asserted-by":"crossref","unstructured":"Hills SL, Walter EB, Atmar RL, Fischer M, Group AJEVW. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019;68:1-33.","DOI":"10.15585\/mmwr.rr6802a1"},{"key":"10.1016\/j.vaccine.2023.01.061_b0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.061_b0020","unstructured":"Food and Drug Administration. Ixiaro. March 30, 2009 Approval Letter. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/ixiaro."},{"key":"10.1016\/j.vaccine.2023.01.061_b0025","unstructured":"VLA-401: JE-VC post-marketing adverse event surveillance among U.S. military personnel. Presentation to: Advisory Committee on Immunization Practices. 2017."},{"key":"10.1016\/j.vaccine.2023.01.061_b0030","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.2105\/AJPH.92.12.1900","article-title":"The defense medical surveillance system and the department of defense serum repository: glimpses of the future of public health surveillance","volume":"92","author":"Rubertone","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2023.01.061_b0035","unstructured":"U.S. Army Public Health Center. Surveillance of COVID-19 in the Department of Defense.TIP No. 98-122-0720."},{"key":"10.1016\/j.vaccine.2023.01.061_b0040","doi-asserted-by":"crossref","unstructured":"Begier EM, Burwen DR, Haber P, Ball R, Vaccine Adverse Event Reporting System Working G. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis. 2004;38:771-9.","DOI":"10.1086\/381548"},{"key":"10.1016\/j.vaccine.2023.01.061_b0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1708-8305.2007.00158.x","article-title":"Safety of Typhim Vi vaccine in a postmarketing observational study","volume":"14","author":"Marcus","year":"2007","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.01.061_b0050","unstructured":"Jackson BR, Iqbal S, Mahon B, Centers for Disease C, Prevention. Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:305-8."},{"key":"10.1016\/j.vaccine.2023.01.061_b0055","first-page":"1","article-title":"Centers for disease C, prevention. Japanese encephalitis vaccines: recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2023.01.061_b0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/clinids\/24.2.265","article-title":"Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine","volume":"24","author":"Berg","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.061_b0065","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0264-410X(97)00020-0","article-title":"Allergic mucocutaneous reactions to Japanese encephalitis vaccine","volume":"15","author":"Plesner","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.061_b0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0887-8994(92)90036-X","article-title":"Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination","volume":"8","author":"Ohtaki","year":"1992","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.vaccine.2023.01.061_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(96)00170-3","article-title":"Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines","volume":"15","author":"Sakaguchi","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.061_b0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.061_b0085","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/j.vaccine.2018.04.038","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012\u20132016","volume":"36","author":"Walker","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:05Z","timestamp":1759404245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000932"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011\u2013August 2019","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}